Target Audience

This activity was developed for pulmonologists, allergists, and other clinicians involved in the management of severe asthma.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

• Describe current evidence for the use of biological-based therapies for the treatment of severe asthma
• Differentiate biological-based therapies for the treatment of severe asthma based on patient- and treatment-related factors
• Utilize genetic information to select the appropriate biological-based therapy for a patient with severe asthma
• Apply updated guidance to optimally utilize biological-based therapy in patients with severe asthma

Faculty

Accreditation

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement

It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.

The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:

Nicola A. Hanania, MD, MS

• Research Support: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline
• Consultant: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Sanofi/Regeneron
• Speaker Bureau: AstraZeneca

Reynold A. Panettieri, Jr, MD

• Research Support: AstraZeneca, Bristol-Myers Squibb, Genentech, Gilead, MedImmune, Oncoarendi, RFIM, Sanofi/Regeneron, Theratrophix, Vertex
• Consultant: AstraZeneca, Boehringer Ingelheim, MedImmune, Novartis
• Speaker Bureau: AstraZeneca, Boehringer Ingelheim, MedImmune, Sanofi/Regeneron, Teva

The faculty for this activity has disclosed that there will be no discussion about the use of products for non-FDA approved applications.

Additional Content Planners

Eugene Cullen, MD (peer reviewer): No significant relationships to disclose

Gregory Scott, PharmD, RPh (medical writer): No significant relationships to disclose

Charles Willis, Director, Continuing Education, consults for Pfizer, Inc.; all other staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient's unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

This activity is supported by educational grants from AstraZeneca and GlaxoSmithKline.

This activity is an online enduring material. Successful completion is achieved by reading and/or viewing the material, reflecting on its implications in your practice, and completing the assessment component.

The estimated time to complete the activity is 1.5 hours.

This activity was originally released on December 15, 2018 and is eligible for credit through December 15, 2019.

Our Policy on Privacy

Annenberg Center for Health Sciences respects your privacy. We don’t share information you give us, or have the need to share this information in the normal course of providing the services and information you may request. If there should be a need or request to share this information, we will do so only with your explicit permission. See Privacy Statement and other information at http://www.annenberg.net/privacy-policy/

Contact Information